Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study

Introduction: Evaluation of the hypothalamic-pituitary-testicular axis and sperm analyses are not a standard examination of patients with Relapsing-Remitting Multiple Sclerosis (RRMS).Methods: This is a prospective-case-controlled study. Patients, aged 18–55, with a confirmed diagnosis of RRMS, naïv...

Full description

Bibliographic Details
Main Authors: Emanuele D'Amico, Aurora Zanghì, Giovanni Burgio, Clara Grazia Chisari, Rosita Angela Condorelli, Sandro La Vignera, Aldo Eugenio Calogero, Francesco Patti
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00756/full
id doaj-6cd131960c2f44f88fbc2c50385eff6a
record_format Article
spelling doaj-6cd131960c2f44f88fbc2c50385eff6a2020-11-25T03:56:22ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-08-011110.3389/fneur.2020.00756537210Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control StudyEmanuele D'Amico0Aurora Zanghì1Giovanni Burgio2Clara Grazia Chisari3Rosita Angela Condorelli4Sandro La Vignera5Aldo Eugenio Calogero6Francesco Patti7Department “G.F. Ingrassia”, MS Center, University of Catania, Catania, ItalyDepartment “G.F. Ingrassia”, MS Center, University of Catania, Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, Catania, ItalyDepartment “G.F. Ingrassia”, MS Center, University of Catania, Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, Catania, ItalyDepartment “G.F. Ingrassia”, MS Center, University of Catania, Catania, ItalyIntroduction: Evaluation of the hypothalamic-pituitary-testicular axis and sperm analyses are not a standard examination of patients with Relapsing-Remitting Multiple Sclerosis (RRMS).Methods: This is a prospective-case-controlled study. Patients, aged 18–55, with a confirmed diagnosis of RRMS, naïve to any DMT were enrolled. Controls were men with normal evaluation who acceded to the Andrology Center of Catania in a contemporary matched randomized fashion to the group of RRMS patients. The aim of the study is to evaluate gonadal steroids and sperm quality in men at the time of RRMS diagnosis and 12 months following the first disease modifying treatment (DMT).Results: Out of 41 patients with RRMS, 38 were included in the study (age 40.3 ± 12.3) to be compared with matched controls. Patients with RRMS showed no differences in gonadal steroids or sperm parameters, except for free testosterone (fT) plasma levels, which were lower in RRMS patients than controls (median 0.09 vs. 1.4, p < 0.0001). The correlation analyses, corrected for age and Body Mass Index, did not reveal any correlation between hormonal/sperm parameters and level of disability or disease activity at onset. Additionally, 12 months following the start of DMT, there were no differences in gonadal steroids and sperm quality compared to baseline.Conclusions: Results suggest that RRMS may not have an impact on fertility status but prospective long-term studies are needed.https://www.frontiersin.org/article/10.3389/fneur.2020.00756/fullmultiple sclerosistestosteronehypothalamic-pituitary-testicular axisdisease modifying therapiesdisease activity
collection DOAJ
language English
format Article
sources DOAJ
author Emanuele D'Amico
Aurora Zanghì
Giovanni Burgio
Clara Grazia Chisari
Rosita Angela Condorelli
Sandro La Vignera
Aldo Eugenio Calogero
Francesco Patti
spellingShingle Emanuele D'Amico
Aurora Zanghì
Giovanni Burgio
Clara Grazia Chisari
Rosita Angela Condorelli
Sandro La Vignera
Aldo Eugenio Calogero
Francesco Patti
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
Frontiers in Neurology
multiple sclerosis
testosterone
hypothalamic-pituitary-testicular axis
disease modifying therapies
disease activity
author_facet Emanuele D'Amico
Aurora Zanghì
Giovanni Burgio
Clara Grazia Chisari
Rosita Angela Condorelli
Sandro La Vignera
Aldo Eugenio Calogero
Francesco Patti
author_sort Emanuele D'Amico
title Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
title_short Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
title_full Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
title_fullStr Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
title_full_unstemmed Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study
title_sort gonadal steroids and sperm quality in a cohort of relapsing remitting multiple sclerosis: a case-control study
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2020-08-01
description Introduction: Evaluation of the hypothalamic-pituitary-testicular axis and sperm analyses are not a standard examination of patients with Relapsing-Remitting Multiple Sclerosis (RRMS).Methods: This is a prospective-case-controlled study. Patients, aged 18–55, with a confirmed diagnosis of RRMS, naïve to any DMT were enrolled. Controls were men with normal evaluation who acceded to the Andrology Center of Catania in a contemporary matched randomized fashion to the group of RRMS patients. The aim of the study is to evaluate gonadal steroids and sperm quality in men at the time of RRMS diagnosis and 12 months following the first disease modifying treatment (DMT).Results: Out of 41 patients with RRMS, 38 were included in the study (age 40.3 ± 12.3) to be compared with matched controls. Patients with RRMS showed no differences in gonadal steroids or sperm parameters, except for free testosterone (fT) plasma levels, which were lower in RRMS patients than controls (median 0.09 vs. 1.4, p < 0.0001). The correlation analyses, corrected for age and Body Mass Index, did not reveal any correlation between hormonal/sperm parameters and level of disability or disease activity at onset. Additionally, 12 months following the start of DMT, there were no differences in gonadal steroids and sperm quality compared to baseline.Conclusions: Results suggest that RRMS may not have an impact on fertility status but prospective long-term studies are needed.
topic multiple sclerosis
testosterone
hypothalamic-pituitary-testicular axis
disease modifying therapies
disease activity
url https://www.frontiersin.org/article/10.3389/fneur.2020.00756/full
work_keys_str_mv AT emanueledamico gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
AT aurorazanghi gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
AT giovanniburgio gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
AT claragraziachisari gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
AT rositaangelacondorelli gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
AT sandrolavignera gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
AT aldoeugeniocalogero gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
AT francescopatti gonadalsteroidsandspermqualityinacohortofrelapsingremittingmultiplesclerosisacasecontrolstudy
_version_ 1724465401327255552